The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
An RNS is possible any day, including today.
Recalling the comment made by Moderna at a recent Event, to our CEO, to the effect that, "if you're right, we're in trouble", it's OK to wonder if Moderna have learnt much more on that theme lately?
Prof. Lindy will surely have had chats at least with BioNTech and Moderna in this adjacency, for sure. Whilst it's fair to bewail our 'missing' RNS, when it arrives, let's hope it proves worth the wait.
I think it possible that with discussions, meets, travel etc., matters Scancell might be busy over there. We'll see . . . GLA
Hi Violin, yes just 38C down here. Surprised no RNS today but IMO it won't be long. I'll try to get back to 'patient' mode for now. ATB
Thanks Burble. I enjoyed this bit : " . . . it does genuinely feel like cancer vaccine science is gaining momentum... the really exciting thing is these results are from clinical trials".
Thanks Chester. Lost in time zones . . . .
I think someone suggested we might get signals from X or linked-in etc. and that would be interesting. GNA
Chester re. yours try this https://uk.advfn.com/cmn/fbb/thread.php3?
With SCLP you can search 2 more threads. And thanks Bermuda.
Inan prolific on PoG. Good effort. Comment on the 'thrust' of it would be interesting. ATB
Thanks again Bermuda for the usual clarity. This data release process seems quite fusty to me but of course there are reasons. So we wait for Monday. ATB
Yes Mia me too, thanks Konar
Thanks Bermuda !
Cleaner my last 'went' early, but many thanks for your 11.36 yesterday and this :-
"Late-breaking and clinical trials abstract text release on April 5, 2024 at 12 p.m. PT/3 p.m. ET"
Getting my head around 3 time zones, would I be correct in thinking that the earliest time BST, of release of the abstract, would be Saturday at 2 pm ? (San Diego 14 hours behind BST ? ).
No RNS until Monday but won't the Abstract be available on the AACR site 2pm Saturday, in which case, an eminent Researcher such as yourself, would be able to get it.
I'm not sure of my ground here but it is interesting.
And would the above apply if Scancell are fortunate to be an "Abstract selected for the official AACR Annual Meeting Press Program". MMmmmm
ATB
Cleaner - * Late-breaking and clinical trials abstract text release on April 5, 2024 at 12 p.m. PT/3 p.m. ET
Hey Violin, I hope the posts from Berm and Ray P cheered you up a little. I see your anxious post brought out the 'gloomsters'.
I was pondering further the strange mention of BioNTech in that RNS again. Without subscribing to the weightier theories, it'd be fair to observe that old Friends and Colleagues in that proximity at AACR, are quite likely to meet, even if only for a chat.
It will be fascinating to see how the two presentations are received.
Keep smiling - we're visiting the North atm and there's a heatwave around 42C plus a forecast to go to 45C. Stifling.
Myself I expect good matters Scancell to roll fast at some point and we may not see it coming. IMO there's just too much here to stay on the shelf much longer.
ATB
Cleaner re. your 07.26 - I stand to be corrected but IMO this is 160,000 new shares issued and to enter the market today. I note that it was on behalf of 'employees', i.e. more than one.
And btw, with all respect, this is the Scancell BB. ATB
Hi Ruck - the word used was 'prime' not 'priming', therefore I favour your Option 1 . . . . maybe Option 3. For me, 2 is a non-runner. It will all surely become clear on Monday . . . . . it's further good news that it we'll be getting an update on SCOPE that has been Authored by the Trial centres.
Inan, happily, has noticed that this RNS cites a different list of Authors to the previous updates. And the Authors appear to be from the SCOPE trial centres !
Yes it looks like an update is coming !
Talking Scancell . . . an interesting and relevant discussion over there on PoG, between Ruck and Inanaco.
Ruck asks, "So what is “prime time” in the context of the presentation title?"
Inan replies :-
"Vaccines are heading for "prime time news coverage" just like the check points did a few years ago. Even though they have approvals .......... they have failures as the industry pushes for very tight marginal improvements across multiple cancers its recent failings in Ovarian highlight the enormous potential if you can make them work.
Scancell has the Red Bull RB20 and the driver ..... what the market forgets, the Immunobody can play on any track along with Moditope.
The full scope of that will come this year as results are presented"
Prime time news coverage - that would be nice . . . GLA
Rob - just checking on PoG I see Inan, back in the action happily, has noticed that this RNS cites a different list of Authors to the previous updates.
And the Authors appear to be from the SCOPE trial centres !
Yes it looks like an update is coming !
Chester/Rob - re. BioNTech I think Scancell are just elaborating on the Symposium that we are presenting under.
Moving on, I wonder if in these words, Scancell are suggesting they will bringing us an update - "SCIB1 previously demonstrated an 85% response rate among 13 first-line advanced melanoma patients".
I.E. - 'Previously' - so there'll be something new on Sunday?